A5080330116- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and B-cell Immunology
- Polyomavirus and related diseases
- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cytomegalovirus and herpesvirus research
- Antifungal resistance and susceptibility
- Immune Cell Function and Interaction
- Renal Transplantation Outcomes and Treatments
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- Immunodeficiency and Autoimmune Disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Immunotherapy and Immune Responses
- Fungal Infections and Studies
- Hemoglobinopathies and Related Disorders
- Eosinophilic Disorders and Syndromes
- Porphyrin Metabolism and Disorders
- Bone and Joint Diseases
Helsinki University Hospital
2014-2023
University of Helsinki
1999-2022
European Society for Blood and Marrow Transplantation
2001-2021
Maastricht University Medical Centre
2018
University Hospital Heidelberg
2008-2017
Heidelberg University
2008-2017
Martin Luther University Halle-Wittenberg
2017
University Medical Center Hamburg-Eppendorf
2010-2017
University of Cologne
2017
University Hospital Leipzig
2017
To evaluate the role of donor lymphocyte infusion (DLI) in treatment relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT).We retrospectively analyzed data 399 patients with AML first hematological relapse HSCT whose did (n = 171) or not 228) include DLI. After correction for imbalances and established risk factors, two groups were compared respect to overall survival. Further, a detailed analysis factors survival among DLI recipients was...
In contrast to autologous bone marrow transplants for hematologic cancers, allogeneic contain no tumor cells that might cause a relapse. We report the results of such transplantation using HLA-compatible sibling donors in 90 patients with multiple myeloma performed 26 European centers between 1983 and 1989.
Purpose Patients with acute myeloid leukemia (AML) and FLT3/internal tandem duplication (FLT3/ITD) have poor prognosis if treated chemotherapy only. Whether this alteration also affects outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) remains uncertain. Methods We analyzed 206 patients who underwent HLA-identical sibling matched unrelated HSCTs reported to the European Group for Blood Marrow Transplantation a diagnosis of AML normal cytogenetics data on FLT3/ITD...
Purpose To compare a reduced-intensity conditioning regimen (RIC) with myeloablative (MAC) before allogeneic transplantation in patients myelodysplastic syndrome (MDS) within randomized trial. Patients and Methods Within the European Society of Blood Marrow Transplantation, we conducted prospective, multicenter, open-label, phase III trial that compared busulfan-based RIC MAC MDS or secondary acute myeloid leukemia. A total 129 were enrolled from 18 centers. randomly assigned 1:1 ratio...
Out of 690 allogeneic matched sibling donor transplants for multiple myeloma reported to the European Group Blood and Marrow Transplantation (EBMT) registry, 334 were performed during period 1983–93 (all with bone marrow) 356 1994–98 [223 marrow 133 peripheral blood stem cells (PBSCs)]. The median overall survival was 10 months patients transplanted earlier time 50 later period. use PBSCs associated engraftment but no significant benefit compared same improvement in since 1994 result a...
Results of allogeneic stem-cell transplantation (allo) in myeloma are controversial. In this trial autologous (auto) followed by reduced-intensity conditioning matched sibling donor allo (auto-allo) was compared with auto only previously untreated multiple myeloma.In all, 357 patients up to age 69 years were enrolled from 2001 2005. Patients an HLA-identical allocated the auto-allo arm (n = 108) and without a 249). Single 145) or tandem 104) optional. Conditioning for melphalan 200 mg/m(2);...
Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients advanced CLL, it is not known whether this holds true for 17p-CLL.Baseline data from patients, whom information on presence of 17p-CLL was available, were downloaded European Group Blood Marrow Transplantation database. Additional course CLL follow-up collected questionnaire.A total 44 received HCT...
Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or busulfan (Bu) are currently the most common myeloablative regimens used in allogeneic stem-cell transplantation (alloSCT) adults acute myelogenous leukemia (AML). Intravenous (IV) Bu has more predictable bioavailability and a safer toxicity profile than oral formulation. Comparative studies of outcomes have been performed between Bu/Cy Cy/TBI, but there no comparative trials era IV Bu.We retrospective registry-based study...
This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. retrospective analysis from EBMT Acute Leukemia Working Party included 473 de novo leukemia in first complete remission who underwent an allogeneic using a human leukocyte antigen-identical sibling or antigen-matched unrelated donor between 2000 2010. Three...
Abstract Patients with acute myeloid leukemia (AML) in morphological first complete remission (CR1) pre‐allogeneic hematopoietic cell transplantation (HCT) may have measurable residual disease (MRD) by molecular and immunophenotyping criteria. We assessed interactions of MRD status HCT conditioning regimen intensity patients aged <50 years (y) or ≥50y. This was a retrospective study the European Society for Blood Marrow Transplantation registry. were >18y AML CR1 NEG/POS recipients...